- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03482219
Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis (REACH)
Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis (The REACH Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The specific aims of this study are to:
Determine the short and longer-term effects of an intensive (8-week in-person occupational therapy treatment with prescribed home exercises) on improving arm function versus home exercise alone.
This study's hypothesis is that immediately following treatment at 8 weeks and at 18 weeks, participants randomized to the in-person occupational therapy will have significant improvements in the QuickDASH disability measure, PROMIS physical function measure, and total active hand function compared to the home exercise alone.
- Determine how adherence to home exercise in both groups influences treatment effects.
This study's hypothesis is that adherence will independently predict improvement in outcomes at 8 and 18 weeks regardless of treatment group assignment and that higher adherence to the home exercise program will result in greater and more long-lasting improvements.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Have a diagnosis of systemic sclerosis including:
- Diffuse cutaneous subset
- Disease duration < 5 years from 1st non Raynaud phenomenon sign or symptom
- Have a contracture of the hand and other joint in at least one arm, such as wrist, elbow, or shoulder, with the ability to demonstrate active range of motion in that arm
- Willing to travel to participate in therapy and outcome assessments.
- Have an Android, iPhone, iPad or computer tablet to load the home exercise App.
- English speaking
Exclusion Criteria:
- issues that preclude meaningful participation in study procedures (e.g. concurrent or complex medical issues, inability to use home exercise app, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intensive treatment
Participants will undergo 8 sessions with an occupational therapist. Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises. The occupational therapy consists of the following which will be provided as appropriate:
|
The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education.
The home app intervention involves one session of education with the occupational therapist.
The app consists of videos depicting each exercise and ability to track adherence to exercises.
|
|
Active Comparator: Home app intervention
Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app.
The app has videos depicting each exercise and ability to track adherence to exercises.
|
The app consists of videos depicting each exercise and ability to track adherence to exercises.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
quickDASH
Time Frame: Change from Baseline at 8 weeks and 18 weeks
|
self-report questionnaire of physical function and symptoms.
This is an 11-item questionnaire in which difficulty in several tasks involving the upper extremity are rated as well as interference and severity of symptoms.
Items are averaged and converted to a 0 - 100 scale; a higher score indicates worse function.
|
Change from Baseline at 8 weeks and 18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical Function
Time Frame: Change from Baseline at 8 weeks and 18 weeks
|
PROMIS physical function 8-item short form.
The US population mean score for this measure is 50 with SD of 10, and a higher score denotes better function
|
Change from Baseline at 8 weeks and 18 weeks
|
|
Total Hand Function
Time Frame: Change from Baseline at 8 weeks and 18 weeks
|
Summary score of degrees of active range of motion in hand.
This is calculated by summing the total active range of motion for each finger and thumb by goniometer (260 degrees in each finger and 135 in the thumb).
A total score of 1125 is possible and a higher score equals more range of motion
|
Change from Baseline at 8 weeks and 18 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Susan Murphy, ScD OTR, Associate Professor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00141111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
AmgenTerminatedDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicSpain, Japan, Romania, United States, Mexico, Argentina, Israel, Greece, Chile, Serbia, South Korea, Italy, Poland, Portugal, United Kingdom
-
Beijing GoBroad HospitalCARsgen Therapeutics Co., Ltd.RecruitingSystemic Lupus Erythematosus (SLE) | Systemic Sclerosis (SSc)China
-
AmgenTerminatedDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicSpain, Serbia
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
argenxRecruitingSystemic Sclerosis (SSc)Croatia, Spain, Denmark, Italy, Germany, Lithuania, United Kingdom, Netherlands, Poland, Belgium, United States, Switzerland, Mexico, Argentina, France, Bulgaria, Chile, Greece, Serbia, Portugal, Puerto Rico, Czechia, Romania, Hungary
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
The Children's Hospital of Zhejiang University...Guangzhou Women and Children's Medical CenterRecruitingSystemic Sclerosis (SSc)China, Christmas Island
-
University of PatrasRecruitingSSc-Systemic SclerosisGreece
Clinical Trials on Occupational therapy
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Alabama at BirminghamCompleted
-
NYU Langone HealthCompletedde Quervain's DiseaseUnited States
-
University of MalagaCompletedWell-being | Individuality | Self-EfficacySpain
-
Kristen PatakiCompletedADHD | Autism Spectrum Disorder | Sensory Processing DisorderUnited States
-
Ankara Medipol UniversityMedipol University; Yeditepe UniversityCompletedCerebral Palsy (CP) | Activities of Daily LivingTurkey (Türkiye)
-
Cliniques universitaires Saint-Luc- Université...CompletedSevere Chronic Obstructive Pulmonary DiseaseBelgium
-
Taipei City HospitalCompletedOccupational Therapy | Psychiatric RehabilitationTaiwan
-
Children's Hospital Medical Center, CincinnatiCompletedAutism Spectrum Disorder | Attention Deficit Hyperactivity DisorderUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityXijing Hospital; Children's Hospital of Fudan University; Shaanxi Provincial... and other collaboratorsUnknownCerebral Palsy | Brain Injury, ChronicChina